Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

0.00%

4.1¢ incannex healthcare limited

Ann: Quarterly Activities Report and Appendix 4C, page-19

First 19 Last

Share
Profile

Follow
Exalted

1,869 Posts.

1472

29/07/20

19:56

Post #: 46164680
Share

Originally posted by Ted Striker: ↑

I’d say rhino your take on it is spot on to my way of thinking.

The original agreement with Cannvalate was to conduct what I would term more proof of concept trials that were designed so that upon success the company could look to immediate sales on the SAS. The company then made the decision to go for global IP protection and pursuit of the FDA registration pathway. As you rightly point out this is a totally different kettle of fish With commensurately massive upside to boot.

The work on ARDS to date would have nothing to do with the original agreement. All of this pre clinical work was never discussed. Camargo would not come cheap and they are consulting on THREE different pathways concurrently.

I don’t understand the questions around R & D spend to be honest. IHL is now a bonafide BIOTECH story. It’s not a cannabis stock as it keeps getting referred to - sure it may sell cannabis oils and inhalers etc that is growing nicely and will underpin the business but pursuing novel drug development for massive markets where there is no existing pharmacological cure via FDA is BIOTECH and its BIG.

I can’t find a biotech that spent less than us on my watchlist and most of them aren’t doing a lot. There are THREE programs runnning here. To put it in perspective We are currently awaiting results on an in vitro study, 2 animal studies and are waiting for ethics approval for a phase 2 trial into OSA where the probability of success is better than most given the positive prior research conducted by Carley into the use of straight dronabinol for OSA.

Btw has anyone noticed that the company is conducting the trial with The Alfred and that they’ve also submitted for ethics approval at The Alfred? Do you think that puts us in pretty good stead?

Ted

Expand

Agreed that IHL is a true Biotech now and should be focused on that as the main point of the biz.

The concern that some are having now is to do with cash balance. We have enough to last 2.7 quarters so we need those options converted to avoid another CR.

Looking forward to the commencement of the OSA Phase 2B Human Trial at the Alfred. Company is progressing well here, just need one bang buster result to proceed into FDA and the punters will come for it big time.
6 Upvote

0 Great analysis

Reply

Top Stories

Revolutionary inverter technology leads the clean energy charge

Brightstar tops votes in 2024 Kalgoorlie Super PITch

RBA keeps rates steady at 4.35%, reflecting expectations

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

From the Floor with Kim Beazley at Diggers and Dealers 2024